Secondary hematological malignancies associated with temozolomide in patients with glioma

Neuro-Oncology

Volumn 15, Issue 10, 2013, Pages 1445-1450

  Momota, Hiroyuki ^a,b   Narita, Yoshitaka ^a,b   Miyakita, Yasuji ^a,b   Shibui, Soichiro ^a,b  

^a NATIONAL CANCER CENTER HOSPITAL   (Japan)

^b NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

alkylating agent; glioma; secondary hematological malignancy; temozolomide

Indexed keywords

CARBOPLATIN; CISPLATIN; ETOPOSIDE; FLUOROURACIL; IFOSFAMIDE; INTERFERON; NIMUSTINE; PROCARBAZINE; TEMOZOLOMIDE; VINCRISTINE;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ADULT; AGED; ANAPLASTIC EPENDYMOMA; ANAPLASTIC GANGLIOGLIOMA; ANAPLASTIC GLIONEURONAL TUMOR; ANAPLASTIC OLIGOASTROCYTOMA; ARTICLE; ASTROCYTOMA; BRAIN STEM GLIOMA; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER RECURRENCE; CANCER SURVIVOR; DISEASE ASSOCIATION; EPENDYMOMA; FEMALE; FOLLOW UP; GLIOBLASTOMA; GLIOMA; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MYELODYSPLASTIC SYNDROME; OLIGODENDROGLIOMA; PILOCYTIC ASTROCYTOMA; PLEOMORPHIC XANTHOASTROCYTOMA; TREATMENT DURATION;

ALKYLATING AGENT; GLIOMA; SECONDARY HEMATOLOGICAL MALIGNANCY; TEMOZOLOMIDE;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS, ALKYLATING; BRAIN NEOPLASMS; CHILD; CHILD, PRESCHOOL; DACARBAZINE; FEMALE; FOLLOW-UP STUDIES; GLIOMA; HEMATOLOGIC NEOPLASMS; HUMANS; INFANT; INFANT, NEWBORN; MALE; MIDDLE AGED; NEOPLASM STAGING; NEOPLASMS, SECOND PRIMARY; PROGNOSIS; RETROSPECTIVE STUDIES; YOUNG ADULT;

EID: 84880550984     PISSN: 15228517     EISSN: 15235866     Source Type: Journal    
DOI: 10.1093/neuonc/not036     Document Type: Article

References (28)

1. Louis, DN, Ohgaki, H, Wiestler, OD, et al. eds. Tumours of the Central Nervous System. World Health Organization Classification of Tumours. Lyon: IARC; 2007.
2. Wen PY, Kesari S. Malignant gliomas in adults. N Engl J Med. 2008;359:492-507.
3. Stewart LA. Chemotherapy in adult high-grade glioma: a systematic review and meta-analysis of individual patient data from 12 randomised trials. Lancet. 2002;359:1011-1018. (Pubitemid 34286538)
4. Shaw EG, Wang M, Coons SW, et al. Randomized trial of radiation therapy plus procarbazine, lomustine, and vincristine chemotherapy for supratentorial adult low-grade glioma: initial results of RTOG 9802. J Clin Oncol. 2012;30:3065-3070.
5. van den Bent MJ, Brandes AA, Taphoorn MJ, et al. Adjuvant procarbazine, lomustine, and vincristine chemotherapy in newly diagnosed anaplastic oligodendroglioma: long-term follow-up of EORTC Brain Tumor Group Study 26951. J Clin Oncol. 2013; 31:344-350
6. Okita Y, Narita Y, Miyakita Y, et al. IDH1/2 mutation is a prognostic marker for survival and predicts response to chemotherapy for grade II gliomas concomitantly treated with radiation therapy. Int J Oncol. 2012;41:1325-1336.
7. Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352:987-996. (Pubitemid 40349501)
8. Stupp R, Dietrich PY, Ostermann Kraljevic S, et al. Promising survival for patients with newly diagnosed glioblastoma multiforme treated with concomitant radiation plus temozolomide followed by adjuvant temozolomide. J Clin Oncol. 2002;20:1375-1382. (Pubitemid 34177445)
9. Su YW, Chang MC, Chiang MF, Hsieh RK. Treatment-related myelodysplastic syndrome after temozolomide for recurrent high-grade glioma. J Neurooncol. 2005;71:315-318.
10. Noronha V, Berliner N, Ballen KK, et al. Treatment-related myelodysplasia/ AML in a patient with a history of breast cancer and an oligodendroglioma treated with temozolomide: case study and review of the literature. Neuro Oncol. 2006;8:280-283. (Pubitemid 46542652)
11. Kim SJ, Park TS, Lee ST, et al. Therapy-related myelodysplastic syndrome/ acute myeloid leukemia after treatment with temozolomide in a patient with glioblastoma multiforme. Ann Clin Lab Sci. 2009;39:392-398.
12. Chamberlain MC, Raizer J. Extended exposure to alkylator chemotherapy: delayed appearance of myelodysplasia. J Neurooncol. 2009;93: 229-232.
13. De Vita S, De Matteis S, Laurenti L, et al. Secondary Ph+ acute lymphoblastic leukemia after temozolomide. Ann Hematol. 2005;84:760-762. (Pubitemid 41447813)
14. Momota H, Narita Y, Miyakita Y, Hosono A, Makimoto A, Shibui S. Acute lymphoblastic leukemia after temozolomide treatment for anaplastic astrocytoma in a child with a germline TP53 mutation. Pediatr Blood Cancer. 2010;55:577-579.
15. Ogura M, Todo T, Tanaka M, et al. Temozolomide may induce therapy-related acute lymphoblastic leukaemia. Br J Haematol. 2011;154:663-665.
16. Villano JL, Letarte N, Yu JM, Abdur S, Bressler LR. Hematologic adverse events associated with temozolomide. Cancer Chemother Pharmacol. 2012;69:107-113.
17. Meadows AT, Friedman DL, Neglia JP, et al. Second neoplasms in survivors of childhood cancer: findings from the Childhood Cancer Survivor Study cohort. J Clin Oncol. 2009;27:2356-2362.
18. Smith MA, McCaffrey RP, Karp JE. The secondary leukemias: challenges and research directions. J Natl Cancer Inst. 1996;88:407-418. (Pubitemid 26097057)
19. Greaves MF. Aetiology of acute leukaemia. Lancet. 1999;349: 344-349. (Pubitemid 27056837)
20. Greene MH, Boice JD, Jr, Strike TA. Carmustine as a cause of acute nonlymphocytic leukemia. N Engl J Med. 1985;313:579. (Pubitemid 15012840)
21. Perry JR, Brown MT, Gockerman JP. Acute leukemia following treatment of malignant glioma. J Neurooncol. 1998;40:39-46. (Pubitemid 28548370)
22. Shaikh AJ, Masood N. Acute lymphoblastic leukemia subsequent to temozolomide use in a 26-year-old man: a case report. J Med Case Rep. 2010;4:274.
23. Pagano L, Pulsoni A, Tosti ME, et al. Acute lymphoblastic leukaemia occurring as second malignancy: report of the GIMEMA archive of adult acute leukaemia. Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto. Br J Haematol. 1999;106:1037-1040. (Pubitemid 29463020)
24. Hunger SP, Sklar J, Link MP. Acute lymphoblastic leukemia occurring as a second malignant neoplasm in childhood: report of three cases and review of the literature. J Clin Oncol. 1992;10:156-163.
25. Kantarjian HM, Keating MJ, Walters RS, et al. Therapy-related leukemia and myelodysplastic syndrome: clinical, cytogenetic, and prognostic features. J Clin Oncol. 1986;4:1748-1757. (Pubitemid 17226663)
26. Rowley JD, Golomb HM, Vardiman JW. Nonrandom chromosome abnormalities in acute leukemia and dysmyelopoietic syndromes in patients with previously treated malignant disease. Blood. 1981;58:759-767. (Pubitemid 11015833)
27. Pui CH, Ribeiro RC, Hancock ML, et al. Acute myeloid leukemia in children treated with epipodophyllotoxins for acute lymphoblastic leukemia. N Engl J Med. 1991;325:1682-1687.
28. Le Deley MC, Leblanc T, Shamsaldin A, et al. Risk of secondary leukemia after a solid tumor in childhood according to the dose of epipodophyllotoxins and anthracyclines: a case-control study by the Société Française d'Oncologie Pédiatrique. J Clin Oncol. 2003;21: 1074-1081. (Pubitemid 46594136)